NEW YORK, April 5 - InforMax today said that a dearth of bookings for its GenoMax technology has contributed to significantly weaker first-quarter results that include lower revenue and a wider net loss.

The company said that revenue for the quarter ended March 31 will be $3.7 million, a 44 percent drop from the $6.6 million it reported during the same period one year ago. Total bookings, meanwhile, fell off 45 percent to $3.9 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.